To understand if this model offers a reliable and rapid platform for identifying pharmacological inhibitors for human MLL-r leukemia, we next addressed whether drugs in preclinical and early-stage clinical studies are efficacious in the Drosophila MLL-AF4 leukemia model. The gene discussed is KMT2A; the disease is leukemia.